Advertisement

Lipoprotein apheresis improves intima media thickness regression: Evidence in the era of new lipid-lowering therapies

  • Francesco Sbrana
    Correspondence
    Correspondence to: U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, 1, 56124 Pisa, Italy.
    Affiliations
    Lipoapheresis Unit – Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana “Gabriele Monasterio”, Via Moruzzi 1, Pisa 56124, Italy
    Search for articles by this author
  • Michele Coceani
    Affiliations
    Interventional Cardiology Division, Fondazione Toscana “Gabriele Monasterio”, Via Moruzzi 1, Pisa 56124, Italy
    Search for articles by this author
  • Beatrice Dal Pino
    Affiliations
    Lipoapheresis Unit – Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, Fondazione Toscana “Gabriele Monasterio”, Via Moruzzi 1, Pisa 56124, Italy
    Search for articles by this author
      Dear Editor,
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Thompson G.R.
        The scientific basis and future of lipoprotein apheresis.
        Ther Apher Dial. 2022; 26: 32-36
        • Koga N.
        • Watanabe K.
        • Kurashige Y.
        • Sato T.
        • Hiroki T.
        Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients.
        J Intern Med. 1999; 246: 35-43
        • Ezhov M.V.
        • Safarova M.S.
        • Afanasieva O.I.
        • Pogorelova O.A.
        • Tripoten M.I.
        • Adamova I.Y.
        • et al.
        Specific lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
        Atheroscler Suppl. 2015; 18: 163-169
        • Safarova M.S.
        • Nugent A.K.
        • Gorby L.
        • Dutton J.A.
        • Thompson W.J.
        • Moriarty P.M.
        Effect of lipoprotein apheresis on progression of carotid intima-media thickness in patients with severe hypercholesterolemia.
        Am J Cardiol. 2022; S0002–9149 ([Epub ahead of print]): 00520-00523
        • Sbrana F.
        • Dal Pino B.
        • Monteleone A.
        • Pasanisi E.M.
        • Petersen C.
        • Ripoli A.
        • et al.
        Evolocumab improves intima media thickness regression in HeFH subjects on lipoprotein apheresis.
        Nutr Metab Cardiovasc Dis. 2020; 30: 2417-2419
        • Sampietro T.
        • Sbrana F.
        • Bigazzi F.
        • Ripoli A.
        • Dal Pino B.
        Null receptor homozygous familial hypercholesterolaemia: quoad valetudinem long life treatment.
        Eur J Prev Cardiol. 2019; (2047487319864191)https://doi.org/10.1177/2047487319864191
        • Sbrana F.
        • Bigazzi F.
        • Dal Pino B.
        • Toma M.
        • Ripoli A.
        • Sampietro T.
        Elusive therapeutic effect of PCSK9 inhibitors on lipoprotein(a) levels.
        Ther Apher Dial. 2019; 23: 385-386
        • Sbrana F.
        • Pino B.D.
        • Bigazzi F.
        • Ripoli A.
        • Volpi E.
        • Fogliaro M.P.
        • et al.
        A large Italian cohort on proprotein convertase subtilisin/kexin type 9 inhibitors.
        Eur J Prev Cardiol. 2020; 27: 2284-2287